Vir Biotechnology Inc. is a biotechnology company focused on leveraging the immune system to develop transformative therapies for infectious diseases and other serious conditions
It aims to create innovative treatments that harness the power of antibodies and other immune-based technologies to target a variety of diseases, including viral infections and immune-related disorders. Through its cutting-edge research and development efforts, the company seeks to improve health outcomes and provide novel solutions to unmet medical needs, with a particular emphasis on addressing global health challenges.
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.
